Why this growth stock could soar 40%+ within 2 years

Stunning gains could be on the horizon for this company.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Healthcare continues to be a rapidly growing sector. An increasing world population which is also ageing provides a tailwind for sales and profitability across a range of healthcare stocks. As such, share price gains could be ahead for companies operating within the industry. Reporting today is one such stock which could record a capital gain of 40% by 2019.

Improving performance

Georgia Healthcare Group (LSE: GHG) is a dominant company in its local market. In fact, it is the largest healthcare services provider, the third largest pharmaceutical retailer and wholesaler, and the largest medical insurance provider in the East European country. As such, its business is relatively well diversified between the three different divisions.

In the 2016 financial year, it was able to record strong results despite a swing to a loss in its medical insurance division. The loss came after a more challenging year, with one large corporate insurance contract having expired and not been renewed. Despite this, its overall performance was strong. Its sales and pre-tax profit increase by over 70%. Furthermore, it remains on target to deliver a more than doubling of its Healthcare Services revenue by 2018 compared to its 2015 level.

Growth outlook

The sharp rise in sales is set to be translated into rising earnings for the company. In 2017, Georgia Healthcare’s bottom line is forecast to rise by 37%, followed by 40% growth in 2018. Despite this strong growth rate, the company’s shares trade on a price-to-earnings growth (PEG) ratio of 0.8. Therefore, if they were to rise in price by 40% they would trade on a PEG ratio of just over 1, which would suggest fair value for money. Certainly, a higher valuation is possible, but a margin of safety may be required due to the company’s lack of geographical, rather than product, diversification.

As mentioned, the healthcare sector could offer strong growth prospects. As such, a number of other companies within the sector may also be worth buying at the present time. For example, Hikma Pharmaceuticals (LSE: HIK) is forecast to record a rise in its bottom line of 37% this year, followed by further growth of 29% next year. This puts it on a PEG ratio of just 0.7, which indicates that it offers superior value for money when compared to Georgia Healthcare.

Risk factor

In addition, Hikma may be a lower-risk business than its healthcare peer. It operates across the globe and so is not dependent on changes in regulations or trading conditions in one country. Hikma has a well-diversified product portfolio, with its focus on generics arguably providing a degree of consistency which some of its healthcare peers lack.

While the developing world may be emerging from a period of austerity, the cost of treatment for an ageing population may become difficult to afford. Therefore, generics may have a more pivotal role to play in future healthcare requirements, with a growing world population also likely to make them increasingly popular. As such, Hikma appears to be a sound buy, with a lower valuation and greater diversity making it a superior option to even the 40%-plus gains which seem to be on offer through Georgia Healthcare.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens has no position in any shares mentioned. The Motley Fool UK has recommended Hikma Pharmaceuticals. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

The market is wrong about this FTSE 250 stock. I’m buying it in April

Stephen Wright thinks investors should look past a 49% decline in earnings per share and consider investing in a FTSE…

Read more »

Black father and two young daughters dancing at home
Investing Articles

1 FTSE 250 stock I own, and 1 I’d love to buy

Our writer explains why she’s eyeing up this FTSE 250 growth phenomenon, and may buy more shares in this property…

Read more »

View of Tower Bridge in Autumn
Investing Articles

The FTSE 100 is closing in on 8,000 points! Here’s what I’m buying before it’s too late!

As the FTSE 100 keeps gaining momentum, this Fool is on the lookout for bargains. Here's one stock he'd willingly…

Read more »